Eupraxia Pharmac Financials

Eupraxia Pharmac (EPRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Eupraxia Pharmac (EPRX) reported a net income of -$38.6M in fiscal year 2025.

Eupraxia Pharmac (EPRX) reported diluted earnings per share of $-1.03 for fiscal year 2025. This represents a -35.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Eupraxia Pharmac (EPRX) has a return on equity of -47.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Eupraxia Pharmac (EPRX) generated -$28.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Eupraxia Pharmac (EPRX) had $86.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Eupraxia Pharmac (EPRX) invested $21.3M in research and development during fiscal year 2025.

Eupraxia Pharmac (EPRX) had 52M shares outstanding as of fiscal year 2025.

Eupraxia Pharmac (EPRX) had a current ratio of 15.12 as of fiscal year 2025, which is generally considered healthy.

Eupraxia Pharmac (EPRX) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Eupraxia Pharmac (EPRX) had a return on assets of -44.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Eupraxia Pharmac (EPRX) had $80.6M in cash against an annual operating cash burn of $28.6M. This gives an estimated cash runway of approximately 34 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Eupraxia Pharmac (EPRX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Eupraxia Pharmac (EPRX) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.